Octreotide therapy in a patient with lung microcytoma

Octreotide therapy in a patient with lung microcytoma

Authors

  • Daniela Adua Reparto di Oncologia Medica “U.O.C. A” Policlinico Umberto I – Università “La Sapienza”, Roma
  • Bruno Gori Reparto di Oncologia Medica “U.O.C. A” Policlinico Umberto I – Università “La Sapienza”, Roma
  • Luciano Stumbo Reparto di Oncologia Medica “U.O.C. A” Policlinico Umberto I – Università “La Sapienza”, Roma
  • Ester Del Signore Reparto di Oncologia Medica “U.O.C. A” Policlinico Umberto I – Università “La Sapienza”, Roma
  • Flavia Longo Reparto di Oncologia Medica “U.O.C. A” Policlinico Umberto I – Università “La Sapienza”, Roma

DOI:

https://doi.org/10.7175/cmi.v4i1S.1064

Keywords:

Small cell lung cancer limited stage, Cromogranine A, Neuron-Specific Enolase, Octreotide, Prophylactic panencefalic radiotherapy

Abstract

We report the case of a 51-year-old woman with limited Small Cell Lung Cancer (SCLC). Cytological diagnosis has been made by fibroscopy. Chemotherapy schedule was cisplatin 30 mg/mq and VP-16 100 mg/mq days 1,2,3 q21 as first line treatment. The serum levels of cromogranine A and NSE (Neuron-Specific Enolase) were higher than normal; for this reason we prescribed, together with chemotherapy, octreotide LAR 30 mg every 28 days. Associated toxicity was easily manageable. Subsequent thoracic and panencefalic prophylactic radiotherapy improved tumour response and quality of life. We continued octreotide LAR 30 mg every 28 days even after the end of chemotherapy, as a maintenance therapy, checking periodically serum levels of NSE and cromogranine A. No side effects were observed.

Downloads

Published

2015-10-13

Issue

Vol. 4 No. 1S (2010)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)